These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26983524)

  • 21. Model-Informed Drug Development: A Regulatory Perspective on Progress.
    Zhu H; Huang SM; Madabushi R; Strauss DG; Wang Y; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):91-93. PubMed ID: 31162631
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug makers and NIH team up to find and validate targets.
    Mullard A
    Nat Rev Drug Discov; 2014 Apr; 13(4):241-3. PubMed ID: 24687051
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pharmaceutical industry and clinical drug research].
    Huttunen MO
    Duodecim; 2000; 116(24):2813-5. PubMed ID: 12077886
    [No Abstract]   [Full Text] [Related]  

  • 24. Ann Arbor community rallies in wake of Pfizer shutdown.
    Shaffer C
    Nat Biotechnol; 2007 Aug; 25(8):829-30. PubMed ID: 17687347
    [No Abstract]   [Full Text] [Related]  

  • 25. Goliath befriends David.
    Clarke T; Pearson H
    Nature; 2001 Nov; 414(6863):482-3. PubMed ID: 11734817
    [No Abstract]   [Full Text] [Related]  

  • 26. Balancing options for health research and development.
    Love J
    Bull World Health Organ; 2012 Nov; 90(11):796-796A. PubMed ID: 23226887
    [No Abstract]   [Full Text] [Related]  

  • 27. An audience with … Wolfgang Plischke.
    Plischke W; Mullard A
    Nat Rev Drug Discov; 2014 Apr; 13(4):252. PubMed ID: 24687059
    [No Abstract]   [Full Text] [Related]  

  • 28. Growing against the grain.
    Boyle M
    Fortune; 2004 May; 149(9):148-9, 152, 154 passim. PubMed ID: 15124331
    [No Abstract]   [Full Text] [Related]  

  • 29. Five ways consortia can catalyse open science.
    Cutcher-Gershenfeld J; Baker KS; Berente N; Flint C; Gershenfeld G; Grant B; Haberman M; King JL; Kirkpatrick C; Lawrence B; Lewis S; Lenhardt WC; Mayernik M; McElroy C; Mittleman B; Shin N; Stall S; Winter S; Zaslavsky I
    Nature; 2017 Mar; 543(7647):615-617. PubMed ID: 28358098
    [No Abstract]   [Full Text] [Related]  

  • 30. Bigger isn't always better.
    Nature; 2002 Jul; 418(6896):353. PubMed ID: 12140518
    [No Abstract]   [Full Text] [Related]  

  • 31. Industry and dermatology research: how well can they work together?
    van Rijswijk L; Caldwell-Brown D
    Dermatol Nurs; 1990 Dec; 2(6):339-42. PubMed ID: 2147383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increase in R&D openness to tackle disease in the developing world.
    Parks L
    Future Med Chem; 2012 Dec; 4(18):2237. PubMed ID: 23234547
    [No Abstract]   [Full Text] [Related]  

  • 34. Developing more open and equitable relationships with industry to improve advancements in clinical research in dermatology.
    Campa M; Ryan C; Menter A
    Br J Dermatol; 2016 Jun; 174(6):1365-9. PubMed ID: 27317287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level.
    Kamel N; Compton C; Middelveld R; Higenbottam T; Dahlén SE
    Eur Respir J; 2008 May; 31(5):924-6. PubMed ID: 18448501
    [No Abstract]   [Full Text] [Related]  

  • 36. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
    Wood J; Sames L; Moore A; Ekins S
    Drug Discov Today; 2013 Nov; 18(21-22):1043-51. PubMed ID: 23968993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does process excellence handcuff drug development?
    Koenig J
    Drug Discov Today; 2011 May; 16(9-10):377-81. PubMed ID: 21349347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Centers for education and research in therapeutics.
    Woosley RL
    Clin Pharmacol Ther; 1994 Mar; 55(3):249-55. PubMed ID: 8143390
    [No Abstract]   [Full Text] [Related]  

  • 40. Bioanalytical outsourcing: transitioning from Pharma to CRO.
    Hayes R
    Bioanalysis; 2017 Aug; 9(15):1149-1152. PubMed ID: 28763257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.